Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Humoral p53 antibody response is a prognostic parameter in ovarian cancer
Autore:
Mayerhofer, K; Tempfer, C; Kucera, E; Hefler, L; Zeisler, H; Kainz, C; Zeillinger, R; Sliutz, G;
Indirizzi:
Univ Vienna, Sch Med, Dept Obstet & Gynecol, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 stet & Gynecol, A-1090 Vienna, Austria
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 1B, volume: 19, anno: 1999,
pagine: 875 - 878
SICI:
0250-7005(199901/02)19:1B<875:HPARIA>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; BREAST-CANCER; SERUM ANTIBODIES; CELLULAR PROTEIN; AUTOANTIBODIES; CELLS; EPITOPES; MUTATION; DISEASE;
Keywords:
p53 gene; serum p53 antibodies; ovarian cancer; prognosis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Mayerhofer, K Univ90ienna, Sch Med, Dept Obstet & Gynecol, Waehringer Guertel 18-20, A-10 Univ Vienna Waehringer Guertel 18-20 Vienna Austria A-1090
Citazione:
K. Mayerhofer et al., "Humoral p53 antibody response is a prognostic parameter in ovarian cancer", ANTICANC R, 19(1B), 1999, pp. 875-878

Abstract

Background: Mutant p53 protein may become the target of a tumor-specific humoral and cellular immune response. Material and Methods: We used a specific qualitative p53 antibody ELISA to investigate serum samples of 33 patients with ovarian cancer taken prior to therapy. Additionally, we sought to evaluate whether p53 antibodies are also present in the sera of 17 patients with benign ovarian tumors. Results: p53 antibodies were detected in 36% ofserum samples. There was a statisically significant association between p53 serum antibody response and poor overall survival (p<0.006). No significant associations were found between p53 antibody status and histological type, histological grade, and tumor stage. In 81% of serum samples, no changesfront p53 antibody negativity to positivity or vice versa during follow-rip were observed. p53 antibodies were also detected in the sera of 18% of patients with benign ovarian tumors. Conclusions: The results of this preliminary study suggest that a p53 antibody response in patients with ovarian cancer is associated with poor prognosis. A qualitative method of p53 antibody detection cannot be used to monitor the clinical course of ovarian cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 00:09:43